J Am Acad Dermatol:CLOVES综合征患儿患Wilms瘤的风险研究

2017-09-27 MedSci MedSci原创

背景:2007年Sapp等首先报道了7例以先天性脂肪瘤过度生长、血管畸形和表皮痣为主要表现的临床病例,将其命名为CLOVE综合征。不同于Proteus综合征以出生后发生、进行性发展、扭曲变;为特点的过度生长方式,CLOVE综合征的增生往往为膨胀性的,同时合并以躯干为主的血管畸形、脂肪组织增生、脊柱侧弯、骨结构肥大,但不扭曲变形引临床表现。2009年Alomari又报道了18例相似病例,指出骨骼异常

背景:2007年Sapp等首先报道了7例以先天性脂肪瘤过度生长、血管畸形和表皮痣为主要表现的临床病例,将其命名为CLOVE综合征。不同于Proteus综合征以出生后发生、进行性发展、扭曲变;为特点的过度生长方式,CLOVE综合征的增生往往为膨胀性的,同时合并以躯干为主的血管畸形、脂肪组织增生、脊柱侧弯、骨结构肥大,但不扭曲变形引临床表现。2009年Alomari又报道了18例相似病例,指出骨骼异常、脊柱侧弯或脊髓异常在该综合征中也较常见,提议更名为CLOVES综合征。
 
此命名由其临床表现而得,前3个字母CLO代表躯干先天性脂肪瘤(congenital lipomatous overgrowth),V表血管畸形(vascular malformations),E代表表皮痣(epidermal nevi),S代表包括多指/趾在内的多种骨骼畸形(scoliosis,and other skeletal anomalies)。CLOVES综合征往往还与Wilms瘤(肾母细胞瘤,Wilms‘tumor)风险增加相关。

目的:本研究旨在评价患者的2个类似条件:弥漫性毛细血管畸形伴过度生长(DCMO)和巨脑畸形-毛细血管畸形(M-CM)中评估Wilms瘤的风险。

方法:来自美国的研究人员在血管异常中心数据库中挑选了符合条件的患者,并回顾性分析了在1998-2016之间DCMO患者和M-CM患者是否表现为Wilms瘤。患者最后一次被随访时的年龄都小于8岁,随访时间都未超过2年。

结果:这项研究共纳入了89例患者:67例DCMO患者,17例M-CM患者,和5个不确定诊断的患者。这些患者都没有进展出Wilms瘤。

局限性:最后随访时的患者年龄小于8岁,而且样本量较小。

结论:DCMO患者似乎并不与 Wilms瘤的风险增加相关。DCMO患者可能不用接受筛查,除非伴有偏侧肥大者。虽然在本研究的队列中没有M-CM进展出Wilms瘤的病例,但文献中有2例M-CM进展出Wilms瘤的相关报告。

原始出处:

Peterman CM, Vadeboncoeur S,et al.Wilms tumor screening in diffuse capillary malformation with overgrowth and macrocephaly-capillary malformation: A retrospective study.J Am Acad Dermatol. 2017 Aug 16. pii: S0190-9622(17)31864-9. doi: 10.1016/j.jaad.2017.06.014. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2055619, encodeId=b27e20556190f, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Aug 31 00:24:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057558, encodeId=c74a205e5580b, content=<a href='/topic/show?id=a10e486872' target=_blank style='color:#2F92EE;'>#CLOVES综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4868, encryptionId=a10e486872, topicName=CLOVES综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Oct 10 22:24:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651889, encodeId=439f16518892c, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sat May 26 00:24:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430972, encodeId=db2414309e2e5, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2055619, encodeId=b27e20556190f, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Aug 31 00:24:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057558, encodeId=c74a205e5580b, content=<a href='/topic/show?id=a10e486872' target=_blank style='color:#2F92EE;'>#CLOVES综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4868, encryptionId=a10e486872, topicName=CLOVES综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Oct 10 22:24:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651889, encodeId=439f16518892c, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sat May 26 00:24:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430972, encodeId=db2414309e2e5, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2055619, encodeId=b27e20556190f, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Aug 31 00:24:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057558, encodeId=c74a205e5580b, content=<a href='/topic/show?id=a10e486872' target=_blank style='color:#2F92EE;'>#CLOVES综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4868, encryptionId=a10e486872, topicName=CLOVES综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Oct 10 22:24:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651889, encodeId=439f16518892c, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sat May 26 00:24:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430972, encodeId=db2414309e2e5, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2018-05-26 lishizhe
  4. [GetPortalCommentsPageByObjectIdResponse(id=2055619, encodeId=b27e20556190f, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Aug 31 00:24:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057558, encodeId=c74a205e5580b, content=<a href='/topic/show?id=a10e486872' target=_blank style='color:#2F92EE;'>#CLOVES综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4868, encryptionId=a10e486872, topicName=CLOVES综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue Oct 10 22:24:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651889, encodeId=439f16518892c, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sat May 26 00:24:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430972, encodeId=db2414309e2e5, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]